The Phase III study will evaluate nemvaleukin alfa, Alkermes’ novel investigational engineered interleukin-2 variant immunotherapy, in combination with Merck’s Keytruda (pembrolizumab), in patients with platinum-resistant ovarian cancer.
Merck and Alkermes Collaborate on Phase III Study for Ovarian Cancer Treatment
- by Nile